Xencor presents new preclinical data from CD28 bispecific antibody platform

Xencor announced that it presented new preclinical data generated from engineered CD28 bispecific antibodies targeting the solid tumor antigens CEACAM5, ENPP3, mesothelin, STEAP1 and Trop-2. For each molecule, in vitro T cell activation was enhanced in combination with a CD3 T cell engager. The data were presented in a poster titled "Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in multiple solid tumors" (Abstract 2983) at the American Association for Cancer Research, or AACR, Annual Meeting in Orlando, Florida. "Xencor has rapidly generated multiple CD28 co-stimulatory bispecific antibodies with potential broad applicability across a range of solid tumors, and each of these programs has demonstrated compelling activity. We are leveraging the plug-and-play nature of our XmAb bispecific antibody platforms to generate and explore additional CD28 drug candidates against a broader universe of solid tumor targets," said John Desjarlais, Ph.D., executive vice president and Chief Scientific Officer at Xencor.